Continued UK Growth for Aerogen
Historically the UK and Ireland have always been well aligned in terms of a common sense approach regarding medtech regulation. John Power, Managing Director and CEO of Aerogen suspects that Brexit could mean that legislation could become largely driven by France and Germany in the future.
“Both of these countries have strong medtech industry bases and want to protect their own companies,” he says. “But it is not an issue of real concern for us or other medtech companies which will continue to do well in the UK and mainland Europe. For us, it’s a possible challenge that can be overcome.”
Read how Aerogen’s global mindset drives export success.
Learn more about Enterprise Ireland’s largest Med Tech event and our cluster of innovative companies at Med In Ireland.